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Abstract 
There are significant inter-individual differences in the levels of gene expression. Through 
modulation of gene expression, cis-acting variants represent an important source of phenotypic 
variation. Consequently, cis-regulatory SNPs associated with differential allelic expression are 
functional candidates for further investigation as disease-causing variants. To investigate whether 
common variants associated with differential allelic expression were involved in breast cancer 
susceptibility, a list of genes was established on the basis of their involvement in cancer related 
pathways and/or mechanisms. Thereafter, using data from a genome-wide map of allelic 
expression associated SNPs, 313 genetic variants were selected and their association with breast 
cancer risk was evaluated then in 46,451 breast cancer cases and 42,599 controls of European 
ancestry ascertained from 41 studies participating in the Breast Cancer Association Consortium. 
The associations were evaluated with overall breast cancer risk and with estrogen receptor 
negative and positive disease. One novel breast cancer susceptibility locus on 4q21 (rs11099601) 
was identified (OR=1.05, P=5.6x10
-6
). rs11099601 lies in a 135 kb linkage disequilibrium block 
containing several genes, including, HELQ, encoding the protein HEL308 a DNA dependant 
ATPase and DNA Helicase involved in DNA repair, MRPS18C encoding the Mitochondrial 
Ribosomal Protein S18C and FAM175A (ABRAXAS), encoding a BRCA1 BRCT domain-
interacting protein involved in DNA damage response and double-strand break (DSB) repair. 
Expression QTL analysis in breast cancer tissue showed rs11099601 to be associated with HELQ 
(P=8.28x10
-14
), MRPS18C (P=1.94x10
-27
) and FAM175A (P=3.83x10
-3
) and explaining 
respectively about 20%, 14% and 1% of the variance in expression of these genes in breast 
carcinomas. 
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Introduction 
Breast cancer is a complex disease with a strong heritable component. Great efforts have been 
made during the last decades to elucidate the underlying etiology of this disease. Three classes of 
breast cancer susceptibility alleles with different levels of risk and prevalence in the population 
are now recognized. High-risk alleles such as BRCA1 [1, 2], BRCA2 [3, 4] and TP53 [5] explain 
approximately 20% of the inherited susceptibility, intermediate-risk alleles in DNA-repair genes 
increase this proportion by ~5% [6-18], and common lower-risk alleles, of which approximately 
100 have been identified to date through genome-wide association studies (GWAS), replication 
and custom genotyping efforts, explain approximately 16% of the risk [19-41]. Recent evidence 
suggests that a substantial fraction of the residual aggregation could be explicable by other 
common variants not yet identified
 
[35, 40].  
Global analysis of genome-wide association study (GWAS) data has shown that the large 
majority of common variants associated with susceptibility to cancer lie in non-coding regions, 
and are presumed to mediate risk through regulation of gene expression [42, 43]. Indeed, 
variations in gene expression occur commonly in the human genome, playing a key role in 
human phenotypic variability [44-46]. Studies of allelic imbalances in expression indicate that 
allele-specific differences among transcripts within an individual can affect up to 30% of loci 
and, at the population level, ~30% of expressed genes show evidence of cis-regulation by 
common polymorphic alleles [47]. Recent evidence has also suggested that differences in gene 
expression play a critical role in the underlying phenotypic variation associated with many 
complex genetic diseases [48]. A recent report performed expression quantitative trait loci (cis-
eQTL) analyses for mRNA expression in five tumor types (breast, colon, kidney, lung and 
prostate) and tested 149 known cancer risk loci for eQTL effects [49]. They observed that 42 of 
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these risk loci were significantly associated with eQTLs in at least one gene within 500 kb, eight 
of which were breast cancer risk loci [49]. Furthermore, a recent study has shown that close to 
half of the known risk alleles for estrogen receptor (ER)-positive breast cancer are eQTLs acting 
upon major determinants of gene expression in tumors [50]. These results suggest that additional 
cancer susceptibility loci may be identified through studying genetic variants affecting regulation 
of gene expression. 
In the current study, we performed a breast cancer association study of 313 genetic variants 
showing evidence of association with differential allelic expression (DAE) selected from 175 
genes involved in cancer etiology. These included genes involved in DNA repair (homologous 
recombination (HR) and DNA interstrand crosslink (ICL) repair), interacting and/or modulating 
BRCA1 and BRCA2 cellular functions, cell cycle control, centrosome amplification and 
AURKA interactions, apoptosis, ubiquitination, known tumor suppressors and mitotic and other 
kinases, as well as sex steroid action and mammographic density. We used genotype data derived 
from the iCOGS (Collaborative Oncological Gene-environment Study) custom array [35] to 
investigate the role of these variants on breast cancer risk.  
 9 
Results 
Overall and subtype-specific breast cancer risk association analyses 
For the one hundred seventy-five selected genes involved in cancer-related pathways, we 
identified a set of 355 genetic variants showing evidence of association with DAE (see S1 Table 
for complete list of genes and SNPs). Of the 355 SNPs originally selected, 313 (representing 227 
independent SNPs with pairwise r
2
<0.1) were successfully genotyped. Thirty-two variants were 
excluded because of low Illumina design scores, and eleven SNPs were excluded because of low 
call-rates and/or evidence of deviation from Hardy Weinberg Equilibrium (P-value<10
-7
), 
respectively. Eighty-two SNPs were originally submitted to be included on the iCOGS array but 
were replaced with surrogates in the final design of the array. Association results with breast 
cancer risk for all 313 SNPs are presented in S2 Table. 
Thirteen SNPs from ten different loci were associated with overall breast cancer risk (P<10
-2
) 
(Table 1). Of these, three SNPs, namely rs11099601, rs656040 and rs738200, had associations 
with an increased overall risk of breast cancer that reached P<10
-4
 (approximate significance cut-
off after Bonferroni correction, given 313 tests). No significant evidence of heterogeneity was 
observed among odds ratios (ORs) for these SNPs among studies (I
2
 and P-values are given in S1 
Fig.). The minor alleles of rs11099601 at 4q21 (OR=1.05, P=5.6x10
-6
), rs656040 at 11q13 
(OR=1.05, P=1.52 x10
-5
), and rs738200 at 22q12.1 (OR=1.09, P=5.32x10
-5
) were associated with 
increased overall risk of the disease. rs11099601 was associated with both ER-positive 
(P=5.22x10
-6
) and ER-negative (P=4.08x10
-4
) breast cancer risk (P for difference 0.93) while 
rs656040 and rs738200 appeared primarily associated with ER-positive disease (P=5.96x10
-5
 and 
P=7.21x10
-6
, respectively), although the difference between ER-positive and ER-negative disease 
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was not statistically significant for these two latter SNPs (P for difference 0.096 and 0.242, 
respectively). Of these three SNPs, only variant rs110099601 represents a novel low penetrance 
breast cancer susceptibility locus. The two other variants, (rs656040 at 11q13 and rs738200 at 
22q12.1) which were not known to be associated with breast cancer risk at the time the current 
study was designed, were identified through the main analyses of the iCOGS array. rs656040 is 
located on 11q13 in the 3’-UTR region of the SNX32 gene, approximately 6.8Kb upstream of 
MUS81, and is associated with differential allelic expression of this latter gene (S2 Fig.). 
rs656040 is partially correlated with rs3903072 (r
2
=0.38), which was previously identified as 
associated with breast cancer risk at P<10
-8 
in the combined GWAS and iCOGS analysis reported 
in Michailidou et al. [35]. Similarly, variant rs738200, located on locus 22q12 in the 
tetratricopeptide repeat domain 28 gene (TTC28), falls within a 610 kb interval (Build 37 
coordinates chr22: 28,314,612–28,928,858) on chromosome 22 recently shown to be associated 
with breast cancer risk (smallest P=8.2×10
−22
, for rs62237573). This interval lies approximately 
100 kb centromeric to CHEK2, and further analysis showed that the associated SNPs were 
correlated with the deleterious CHEK2 variant c.1100delC and adjustment for this variant 
suggested the signal is driven by CHEK2 c.1100delC [40]. rs738200 was genotyped as a 
surrogate to our originally selected SNP for this locus (rs9620797), and therefore no allelic 
expression data were available for this SNP. 
All variants associated with overall breast cancer risk with P<10
-2
 included in Table 1 were also 
evaluated for association with breast cancer risk in BRCA1 and BRCA2 mutation carriers within 
the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA) in a total of 15 
252 BRCA1 and 8 211 BRCA2 carriers. However, none of the SNPs showed associations with 
breast cancer risk, including rs11099601, which had a P-value of 0.89 and 0.78 in BRCA1 and 
BRCA2 carriers respectively. 
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rs11099601 lies on 4q21 in a region containing numerous genes including FAM175A 
(ABRAXAS), HELQ and MRPS18C. It was selected on the basis of its association with differential 
allelic expression in FAM175A (see S2 Fig.). In order to further map the novel association at this 
locus, we imputed genotype data for 2,456 common variants across a 500 kb region centered on 
rs11099601 (chr4: 84,132,874-84,631,193 from GRCh37/hg19) using the March 2012 release of 
the 1000 Genomes Project as a reference panel. Subsequent association analysis for overall breast 
cancer risk revealed that rs11099601 was located in a region of approximately 135 kb exhibiting 
strong LD (Fig. 1). SNP rs11099601 remained one of the most strongly associated SNPs, along 
with three other perfectly correlated imputed SNPs (r
2
 =1.0), namely rs4235062 (P=2.40x10
-6
), 
rs6838225 (P=3.70x10
-6
) and rs13142756 (P=4x10
-6
) (Fig.1) (S3 Table). 88 SNPs were strongly 
correlated with rs11099601 (r
2
>0.8; S4 Table) and hence not distinguishable as potential causal 
variants on the basis of association data alone.  
Functional annotation of locus 4q21 
In order to identify potential candidate causal variants at the 4q21 locus, we overlaid the 
associated variants with publicly available functional annotations. The analysis was performed on 
the subset of 88 variants strongly correlated with the lead SNP, rs11099601 (r
2
>0.8). We first 
performed analyses using RegulomeDB (http://www.regulomedb.org) in order to obtain a 
predicted score of functionality for the set of variants. Interestingly, variant rs11099601 was one 
of three variants with the highest scores, along with rs1494961 and rs6535481. The 
corresponding RegulomeDB score (1f) (S4 Table) suggests that these variants are likely to affect 
transcription factor binding and to be linked to expression of a target gene. The scores for the 
other three strongest associated SNPs, namely rs4235062, rs6838225 and rs13142756, were not 
suggestive of functionality (S4 Table – for a description of the RegulomeDB scoring scheme and 
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referenced datatypes refer to http://www.regulomedb.org). Five other highly correlated SNPs 
(rs10008742, rs6844460, rs7691492, rs526064, rs813298), however, also had high scores (2b), 
albeit lower than that of the lead SNP rs11099601, indicative of likely affecting transcription 
factor binding. 
We then analysed ENCODE chromatin biofeatures, namely DNase I hypersensitivity, chromatin 
state segmentation by HMM (chromHMM) and histone modifications of epigenetic markers 
H3K4, H3K9 and H3K27 in all breast cell lines available in ENCODE, including breast 
myoepithelial cells, HMEC mammary cell line, and breast cancer cell line MCF-7. Analysis of 
these biofeatures revealed an overlap between H3K9Ac, a histone mark associated with active 
promoters, and our candidate variant, rs11099601 in breast myoepithelial cells. Further analysis 
of other genotyped and imputed variants correlated with rs11099601, revealed that only 
rs6844460 (P=4.2x10
-6
, r
2
=0.967) overlapped with several chromatin biofeatures in mammary 
cells. rs6844460, which is located within intron 1 of FAM175A, overlapped with a DNase 
hypersensitivity site in MCF-7 cells, with H3K4me3 histone marks (associated with active 
promoters) in breast myoepithelial cells, HMEC and MCF-7 cell lines, with H3K9Ac histone 
marks in both breast myoepithelial cells and HMEC cells, and with H3K27Ac histone marks in 
HMEC. ChromHMM data also predicts that this variant lies within an active promoter region in 
breast cell lines (Fig. 2A). Moreover, rs6844460 overlapped with a binding site for transcription 
factor Max (MYC Associated Factor X) in MCF7 cells. 
In order to identify potential target genes, we analysed enhancer-promoter interactions using 
ChiA-PET data for CCCTC-binding factor (CTCF) and DNA polymerase II (PolII) in MCF-7 
breast tumour derived cells. Multiple, dense, chromosomal interactions were observed in ChiA-
PET data for PolII across most of the entire locus, especially in the region encompassing 
rs11099601, in the vicinity of the promoter regions of HELQ, MRPS18C and FAM175A genes. 
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ChiA-PET data for CTCF in MCF-7 cells showed fewer interactions, none of which 
encompassed variant rs11099601. Similarly Hi-C data revealed few interactions in HMEC cells, 
none of which included our top candidate SNP (Fig. 2B). 
Lastly, although super-enhancers mapped to the 4q21 locus in HMEC mammary cells, none 
overlapped with our top candidate SNPs (Fig. 2C). Predicted enhancer-promoter interactions 
were observed with the promoters of AGPAT9, COQ2, HELQ and MRPS18C genes in HMEC 
cells. However amongst these, only interactions with MRPS18C overlapped with our top putative 
candidate functional variants (rs11099601 and rs6844460) (Fig. 2C). 
Analysis of RNASeq data from ENCODE showed high levels of expression for MRPS18C in 
both HMEC and MCF-7 while HELQ and FAM175A are expressed at very low levels in these 
cell lines (Fig. 2D). However, as illustrated in Fig. 3, analysis of TCGA breast cancer RNAseq 
data in primary tumor (n=765), adjacent normal (n=93) and metastasis (n=6) showed that HELQ, 
FAM175A and HPSE, but not MRPS18C, were all found to be differentially expressed between 
normal breast and tumor tissue (P=1x10
-45
, P=6.6x10
-31
, P=7.3x10
-10
, and P=0.28, respectively, 
as determined by a Kruskal-Wallis rank sum test). Further analysis comparing the tumor 
expression levels of these genes between the 5 molecular subtypes of breast cancer, namely: 
Luminal A, Luminal B, Her2-enriched, Basal-like and Normal-like, showed that while HELQ and 
FAM175A expression levels are decreased in Basal-like tumors (P=1.3x10
-18
 and P=3.5x10
-36
, 
respectively (Kruskal-Wallis test), MRPS18C and HPSE expression were found to be up 
regulated in Basal-like carcinomas (P=1.2x10
-5
, P=1.6x10
-33
) (Fig. 4).  
Expression Quantitative Trait Locus Analysis (eQTL) in breast tissue 
In order to identify associations between candidate variants and expression levels of genes within 
the 4q21 region, we analyzed all genotyped and imputed SNPs within a 1Mb region centered 
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around the most significant SNP (rs11099601), in normal and breast cancer tissue. Significant 
eQTL associations were observed for numerous SNPs in the region in both normal breast and 
tumors (Fig. 5). In the breast cancer tissue dataset BC241, the most strongly expression-
associated SNP at this locus was our top risk SNP rs11099601, which was associated with 
expression levels of HELQ, (with P=8.28x10
-14
 and r
2
=0.20, where the r
2
 value indicates the 
percentage of variance in HELQ expression levels explained by rs11099601) (Fig. 6A). A 
decrease in HELQ expression levels was observed with increasing copy number of the 
rs11099601 (C) allele (Fig. 6A). Multiple SNPs within the 1 Mb region were also associated with 
expression of HELQ, all of which were correlated with rs11099601 (r
2
>0.3). No significant 
eQTLs were observed between rs11099601 and other genes in this region, namely COQ2, HPSE, 
MRPS18C, FAM175A, or AGPAT9, using data from the BC241 sample set.  
In the TCGA BC765 breast cancer dataset, HELQ expression levels were not associated with 
rs11099601 (P=0.34 and r
2
=0.00099) (Fig. 6B) or with any other SNPs in this region. Weak 
associations were only observed between rs11099601 and expression levels for MRPS18C 
(P=1.25x10
-4
 and r
2
=0.02) (Fig. 6F) and FAM175A (P=3.83x10
-3
 and r
2
=0.011) (Fig.6H). 
As HELQ and MRPS18C can be transcribed into several different isoforms, further isoform-
specific analysis was performed in the TCGA BC765 breast cancer dataset. Indeed, in contrast to 
the expression data generated from the Norwegian sample sets, which were obtained using 
expression arrays, expression data from the TCGA datasets used in the current study were 
obtained by RNA-Sequencing, thus allowing further analysis of different gene isoforms. Thus, in 
the BC765 dataset, these analyses resulted in the identification of significant eQTLs for an 
isoform of HELQ (uc101ikb) (P=2.71x10
-11
 and r
2
=0.056) (Fig. 6C), corresponding to a long 
isoform of the gene with one exon lacking. These analyses also further revealed highly significant 
associations for the MRPS18C isoform uc003hor (P=1.94x10
-27
 and r
2
=0.143) (Fig. 6G). 
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Similar to what is observed in the TCGA BC765 breast cancer dataset, gene-normalized analysis 
in the TCGA normal breast tissue dataset NB93 did not reveal significant associations between 
HELQ expression levels and rs11099601 (P=0.15 and r
2
=0.017) (Fig. 6D) while isoform-
normalized analysis showed associations with HELQ isoform uc101ikb (P=9.90x10
-05
 and 
r
2
=0.153) (Fig. 6E). 
In normal breast tissue from the NBCS (NB116), the strongest eQTLs were observed for HPSE, 
where rs11099601 was associated with a decrease in HPSE expression levels (P=4.57x10
-3
, 
r
2
=0.0645) (Fig. 6I). rs11099601 was not associated with the expression levels of any other genes 
in this region. 
Although associations were detected between several genes and our top risk SNP in the different 
sample sets, a lack of consistency in eQTL associations between the two breast cancer sample 
sets was observed. It should be noted that expression data were obtained trough different 
approaches as previously mentioned, i.e expression array (44K Agilent array) for BC241 and 
RNA-Sequencing for BC765 (Illumina RNAseq). Moreover, there are differences in the overall 
PAM50 subtype distributions between these two sample sets. As depicted in S3 Fig., differences 
are noted mainly in the distribution of Luminal A (28.22% in BC241 compared to 49.33% for 
BC765), Her2 (15.35% in BC241 compared to 8.16% for BC765) and Normal-like (14.52% in 
BC241 compared to 2.41% for BC765) subtypes. Expression levels of HELQ, and of other 
candidate genes, were shown to vary significantly between these molecular subtypes (Fig. 4) and 
thus a different distribution of these subtypes between the two sample sets could explain the 
underlying lack of replication in the eQTL analyses.  
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Discussion 
It is well recognized that genetic variants located in genomic regions that regulate gene 
expression are major causes of human diversity and may also be important susceptibility factors 
for complex diseases and traits. Indeed, it has been shown that approximately 30% of expressed 
genes show evidence of cis-regulation by common polymorphic alleles [47]. Moreover, in recent 
years, GWAS have identified thousands of variants associated with various diseases/traits, ~90% 
of which localize outside of known protein-coding regions [42, 43], implicating a regulatory role 
for these variants.  
In the present study, we have assessed the association with breast cancer risk of 313 regulatory 
SNPs in genes involved in the etiology of cancer (see S1 Table for complete list of SNPs and 
genes), in 46,451 breast cancer cases and 42,599 controls of European ancestry. Using this 
approach, we identified rs11099601 (OR=1.05, P=5.6x10
-6
), a novel breast cancer susceptibility 
locus on chromosome 4q21. Analysis of imputed SNPs across a 500Kb region surrounding 
rs11099601 revealed that this variant remained one of the strongest risk signals, tagging a set of 
76 strongly correlated SNPs across a 135Kb LD block containing several genes, including 
COQ2, HPSE, HELQ, MRPS18C, FAM175A (ABRAXAS) and AGPAT9. 
Functional annotation of the 4q21 locus with ENCODE biofeatures in mammary cell lines 
pointed toward rs11099601 as one of the most likely functional variants in this region. eQTL 
analysis showed significant eQTLs in normal and breast cancer tissue for several variants in the 
4q21 region, including rs11099601. The strongest associations for rs11099601 and expression 
were observed in breast carcinomas for MRPS18C and HELQ and explain approximately 14% 
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and 20% of their expression variance, respectively (Fig. 6). Other genes whose expression 
correlated with this eQTL included HPSE and FAM175A. 
These genes represent interesting candidates for further analyses related to breast cancer 
susceptibility. Indeed, analysis of TCGA breast cancer RNAseq data showed that HELQ, 
FAM175A and HPSE were found to be differentially expressed between normal breast and tumor 
tissue and further analysis showed that HELQ and FAM175A expression levels are significantly 
decreased in basal-like tumors.  
HELQ is a single-stranded DNA-dependent ATPase and DNA helicase involved in DNA repair 
and signaling in response to ICL. Genetic disruption of HELQ in human cells enhances cellular 
sensitivity and chromosome radial formation by the ICL-inducing agent mitomycin C (MMC). 
After treatment with MMC, reduced phosphorylation of CHK1 occurs in knockout cells and 
accumulation of G2/M cells is reduced [51]. Furthermore, it was recently shown that Helq 
helicase-deficient mice exhibit subfertility, germ cell attrition, ICL sensitivity, and tumor 
predisposition [52]. A meta-analysis of 22 GWAS, as well as a recent GWAS involving ~70,000 
women performed in the BCAC, have both identified rs4693089, located in an intron of HELQ 
and perfectly correlated with rs11099601, as associated with age at natural menopause 
(p=2.4x10
-19 
and
 
p=9.2x10
-23
, respectively) [53, 54]. Moreover, a GWAS of upper aero-digestive 
tract cancers conducted by the International Head and Neck Cancer Epidemiology Consortium 
identified rs1494961, a missense mutation V306I in the second exon of HELQ gene perfectly 
correlated with rs11099601 (r
2
=1), to be associated with increased risk of upper aero-digestive 
tract cancers in their combined analysis (P=1x10-8) [55]. Another study by the same group 
analyzed the role of DNA repair pathways in upper aero-digestive tract cancers [56]. This study 
showed that the polymerase pathway, to which the HELQ gene belongs, is the only pathway 
significant for all upper aero-digestive tract cancer sites combined and that this association is 
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entirely explained by the association with rs1494961 (P=2.65×10
-4
) [56]. Finally, a recent study 
reported the mutation screening of HELQ in 185 Finnish breast or ovarian cancer families [57]. 
This study did not provide evidence for a role of HELQ in breast cancer susceptibility in the 
Finnish population, but analyses in other populations and larger datasets are needed to further 
assess its role in breast cancer predisposition [57], especially with regard to the involvement of 
rare variants. In the current study, we have shown HELQ to be differentially expressed between 
normal breast and tumor tissue and to be significantly down regulated in basal-like breast tumors 
compared to ER positive tumors, suggesting that altered gene expression levels, potentially 
mediated through the effect of regulatory variants, could be one of the mechanisms contributing 
to breast cancer susceptibility. Previous studies have provided some evidence, in known breast 
cancer susceptibility genes BRCA1 [58] and BRCA2 [59], of genetic variants associated with 
allelic expression differences which could affect the risk of breast cancer in mutation carriers 
through altering expression levels of the wild-type allele. Also, a recent study showed suggestive 
associations between DAE associated variants located in breast cancer susceptibility 
chromosomal regions, and prognosis (ZNF331 and CHRAC1) [60].  
Another gene in this locus, FAM175A, is involved in DNA damage response and double-strand 
break (DSB) repair. It is a component of the BRCA1-A complex, acting as a central scaffold 
protein that assembles the various components of the complex and mediates the recruitment of 
BRCA1 [61-63]. Further evidence rendering FAM175A/ABRAXAS an interesting candidate gene 
is a recent report showing that both homozygous and heterozygous Abraxas knockout mice 
exhibited decreased survival and increased tumor incidence [64]. This study also showed that 
somatic deletion of the ABRAXAS locus on chromosome 4q21 is found in human ovarian and 
breast cancers (especially basal subtype), and this loss is well correlated with reduced ABRAXAS 
expression in these cancers [64]. Moreover, Solyom et al. reported a novel germline ABRAXAS 
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mutation (p.Arg361Gln) in Northern Finnish breast cancer families which affects the nuclear 
localization of the protein and consequently reduces the formation of BRCA1 and Rap80 foci at 
DNA damage sites, leading to ionizing radiation hypersensitivity of cells and partially impairing 
the G2/M checkpoint [65]. In the current study, FAM175A expression was found to be 
significantly down-regulated in ER negative breast tumors. Our group has also, in parallel to the 
present study, conducted a population-based case-control mutation screening study of the coding 
exons and exon/intron boundaries of ABRAXAS in 1250 breast cancer cases and 1250 controls 
from the Breast Cancer Family Registry, including individuals from different ethnic groups such 
as Caucasian, Latino, East Asian and African-American ancestry. Although this study did not 
reveal evidence of association of the identified variants with breast cancer risk, two variants were 
identified and were shown to diminish the phosphorylation of -H2AX, an important biomarker 
of DNA double-strand breaks [66]. 
Lastly, MRPS18C encodes a protein that belongs to the ribosomal protein S18P family, which 
includes three proteins (MRPS18A, MRPS18B, MRPS18C) having significant sequence 
similarity to bacterial S18 proteins. MRPS18C is part of the small subunit (28S) of the 
mitochondrial ribosome involved in oxidative phosphorylation and thus the role of this protein in 
breast cancer susceptibility is unclear. It was reported that MRPS18B (MRPS18-2) binds to RB 
[67] and prevents the formation of the E2F1-RB complex that leads to elevated levels of free 
E2F1 protein in the nucleus and the subsequent promotion of S phase entry [68]. Overexpression 
of human MRPS18B caused transformation of terminally differentiated rat skin fibroblasts and 
transformed cells became tumorigenic in SCID (severe combined immunodeficiency) mice [69]. 
These transformed cells showed anchorage-independent growth and loss of contact inhibition; 
they expressed epithelial markers, showed increased telomerase activity, disturbance of the cell 
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cycle, and chromosomal instability, leading the authors to suggest that MRPS18B is a newly 
identified oncoprotein [69]. Although these results suggest that MRPS18B may be involved in 
carcinogenesis, there is currently no evidence showing that MRPS18C is involved in processes 
other than oxidative phosphorylation. 
Conclusion 
Phenotypic differences among cell types, individuals, and populations are determined by 
variation in gene expression, a substantial proportion of which is driven by genetic variants 
residing in regulatory elements near the affected genes. Analysis of variants associated with 
differential allelic expression has allowed us to identify a novel locus on chromosome 4q21 
associated with breast cancer risk. Subsequent tissue specific eQTL analyses have confirmed 
significant eQTLs for this locus in both normal and breast cancer tissue.  
At the time of study design, data on differential allelic expression was not available in breast 
tissue, leading us to perform the selection of candidate variants in other cell types such as 
lymphoblastoid cell lines, fibroblasts and monocytes. This constitutes a limitation of our study 
which may explain why some of the associations observed between the selected variants and 
DAE in these cells types were not replicated in the eQTL analyses performed in normal breast 
and/or breast cancer cells. Indeed, SNPs associated with variation in gene expression have now 
been mapped for a variety of tissues, highlighting their tissue dependent properties and the need 
for expression profiling of a diverse panel of cell types. 
Hence, further functional characterization of the 4q21 locus, and replication in a larger dataset, 
would be relevant to provide more robust evidence of the involvement of this region in breast 
cancer susceptibility as well as identify the gene(s) and biological mechanism(s) underlying this 
susceptibility.  
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Materials and Methods 
Sample Selection 
A total of 46,451 breast cancer cases and 42,599 controls of European ancestry were included 
from 41 studies participating in the Breast Cancer Association Consortium (BCAC). Studies were 
population-based or hospital-based case-control studies, including nested case-control studies 
within cohorts. Some studies selected cases by age, or oversampled cases with a family history 
(S5 Table). Studies provided ~2% of samples in duplicate for quality control purposes (see 
below). Study subjects were recruited on protocols approved by the Institutional Review Boards 
at each participating institution, and all subjects provided written informed consent. 
SNP Selection 
SNP selection was performed by first identifying a list of genes of interest, which was determined 
by the involvement of these genes in cancer related pathways and/or mechanisms. The list of 
genes was established by researching published results and/or by using available public databases 
such as the Kyoto Encyclopedia of Genes and Genomes (KEGG) (http://www.genome.jp/kegg/). 
Thereafter, DEA SNPs falling within these gene regions were identified using previously 
reported data on allelic expression cis-associations, derived using: 1) the llumina Human1M-duo 
BeadChip for lymphoblastoid cell lines from Caucasians (CEU population) (n=53) [47], the 
Illumina Human 1M Omni-quad for primary skin fibroblasts derived from Caucasian donors (n = 
62) [49, 70], and the Illumina Infinium II assay with Human 1.2 M Duo custom BeadChips v1 for 
human primary monocytes (n=188) [71]. Briefly, 1000 Genomes project data was used as a 
reference set (release 1000G Phase I v3) for the imputation of genotypes from HapMap 
individuals. Untyped markers were inferred using algorithms implemented in IMPUTE2. The 
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unrelated fibroblast panel consisted of 31 parent-offspring trios, where the genotypes of offspring 
were used to allow for accurate phasing. Mapping of each allelic expression trait was carried out 
by first normalizing allelic expression ratios at each SNP using a polynomial method [72] and 
then calculating averaged phased allelic expression scores across annotated transcripts, followed 
by correlation of these scores to local (transcript +/-500 kb) SNP genotypes in fibroblasts as 
described earlier [70]. 
Three hundred fifty-five genetic variants were selected on the basis of evidence of association 
with DAE in 175 genes involved in cancer-related pathways as described above (see S1 Table for 
complete list of SNPs and genes). Following selection, SNPs were submitted for design and 
inclusion on a custom Illumina Infinium array (iCOGS), as part of a BCAC genotyping initiative 
(see Genotyping and Quality Control section below). After undergoing design and post-
genotyping quality control, 313 SNPs remained for analysis. 
Genotyping and Quality Control 
Genotyping was carried out as part of a collaboration between BCAC and three other consortia 
(the Collaborative Oncological Gene-environment Study, COGS). Full details of SNP selection, 
array design, genotyping and post-genotyping quality control (QC) have been published [35]. 
Briefly, three categories of SNPs were chosen for inclusion on the array: (i) SNPs selected on the 
basis of pooled GWAS data, (ii) SNPs selected for the fine-mapping of published risk loci and 
(iii) candidate SNPs selected on the basis of previous analyses or specific hypotheses. The 313 
SNPs described in the current study were candidate SNPs selected on the basis of the hypothesis 
that regulatory variants are involved in breast cancer susceptibility. In general, only SNPs with an 
Illumina design score of 0.8 or greater were considered. SNPs were preferentially accepted if 
they had a design score of 1.1 (i.e. had previously been genotyped on an Illumina platform). If 
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not, we sought SNPs with r
2
=1 with the selected SNP, and selected the SNP with the best design 
score. If no such SNP was available, we selected SNPs with r
2
>0.8 with the chosen SNP, and 
selected the SNP with the best design score. For the COGS project overall, genotyping of 
211,155 SNPs in samples was conducted using a custom Illumina Infinium array (iCOGS) in four 
centers. Genotypes were called using Illumina’s proprietary GenCall algorithm. Standard quality 
control measures were applied across all SNPs and all samples genotyped as part of the COGS 
project [35]. After quality control, genotype data were available for 48 155 breast cancer cases 
and 43 612 controls, and call rates for all SNPs were >95%. 
Statistical Analysis 
Per-allele log-odds ratios (ORs) were estimated using logistic regression, adjusted for principal 
components and study, as described previously [35]. P-values were estimated using Wald test. 
For imputation, genotype data from 48,155 breast cancer cases and 43,612 controls were used to 
estimate genotypes for other common variants across a 500 kb region on chromosome 4 (chr4: 
84,132,763-84,632,763 - NCBI build 37 assembly), with IMPUTE v.2.2 and the March 2012 
release of the 1,000 Genomes Project as reference panel. In all analyses, only SNPs with 
imputation information/accuracy r2>0.30 were considered [40].  
Linkage Disequilibrium  
LD values were computed using 118 independent individuals from the CEU population of the 
1,000 Genome dataset (v3, release 20110521, downloaded from 1000genomes.ebi.ac.uk on April 
2013) [73]. The relevant subset was extracted from the raw data using VCFtools (v0.1.7) [74] and 
the paired r
2
 statistics were obtained for all target loci using PLINK! (v1.07) [75]. The linkage 
heatmaps and the association plots were produced on the R platform (v3.0) using the package 
LDheatmap [76]. 
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Breast cancer association analyses performed in BRCA1 and BRCA2 mutation carriers. 
Associations with breast cancer risk were evaluated within a retrospective cohort framework, by 
modelling the retrospective likelihood of the observed genotypes conditional on the disease 
phenotype. These analyses are described in detail elsewhere [77, 78]. 
Functional annotation 
Two publicly available tools, RegulomeDB [79] and HaploReg V4 [80], were also used to 
evaluate candidate variants. For a full description of the RegulomeDB scoring scheme refer to 
(http://www.regulomedb.org).  
Publicly available genomic data was also used to annotate each SNP most strongly associated 
with breast cancer risk at locus 4q21 (for data sources refer to S6 Table). The following 
regulatory features were obtained for breast cell types from ENCODE and NIH Roadmap 
Epigenomics data through the UCSC Genome Browser: DNase I hypersensitivity sites, 
Chromatin Hidden Markov Modelling (ChromHMM) states, histone modifications of epigenetic 
markers more specifically commonly used marks associated with enhancers (H3K4Me1 and 
H3K27Ac) and promoters (H3K4Me3 and H3K9Ac), and transcription factor ChiP-seq data. 
To identify putative target genes, we examined potential functional chromatin interactions 
between distal and proximal regulatory transcription-factor binding sites and the promoters at the 
risk loci, using the Chromatin Interaction Analysis by Paired End Tag (ChiA-PET) and Genome 
conformation capture (Hi-C, 3C and 5C) datasets downloaded from GEO.  
Maps of active mammary super-enhancer regions in HMEC cells were obtained from Hnisz et al. 
[81]. Predicted enhancer-promoter determined interactions were obtained from the integrated 
method for predicting enhancer targets (IM-PET) described in He et al. [82]. 
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RNA-Seq data from ENCODE was used to evaluate the expression of exons across the 4q21 
locus in HMEC and MCF7 cell lines. For HMEC and MCF7, alignment files from 4 and 19 
expression datasets respectively were downloaded from ENCODE using a rest API wrapper 
(ENCODExplorer R package) [83] in the bam format and processed using metagene R packages 
[84] to normalize in Reads per Millions aligned, and to convert in coverages.  
eQTL analyses 
The influence of germline genetic variations on gene expression was assessed using a linear 
regression model, as implemented in the R library eMAP 
(http://www.bios.unc.edu/~weisun/software.htm). An additive effect was assumed by modeling 
subjects’ copy number of the rare allele, i.e. 0, 1 or 2 for a given genotype. Only relationships in 
cis (defined as those in which the SNP resided less than 1 MB up or down from the center of the 
transcript) were investigated. eQTL analyses were performed on both normal breast and tumor 
tissues, and included the following materials: Normal Breast: NB116 (n=116) consists of samples 
from women of Caucasian ancestry recruited in Oslo, comprising expression data from normal 
breast biopsies (n=73), reduction plastic surgery (n=34) and adjacent normal (n=9) (adjacent to 
tumour). Genotyping was performed using the iCOGS SNP array, and gene expression levels 
were measured with Agilent 44K [85, 86]. NB93 is the Caucasian fraction of the TCGA dataset 
for which adjacent normal breast expression data were available, n=93 for the data normalized 
per gene, and n=94 for the data normalized per isoform. Birdseed processed germline genotype 
data from the Affy6 SNP array were obtained from the TCGA dbGAP data portal [87]. Gene 
expression levels were assayed by RNA sequencing, RSEM (RNAseq by Expectation-
Maximization, [88] normalized both per gene and per isoform, as obtained from the TCGA 
consortium [87]. The data was log2 transformed, and unexpressed genes were excluded prior to 
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eQTL analysis. Breast carcinomas: BC241, is a Caucasian sample set recruited from Oslo, 
n=241. The sample set includes all stages of breast cancer, and genotypes were obtained with the 
iCOGS SNP array, and mRNA expression data was from the Agilent 44K array [86, 89]. BC765 
comprises samples from the TCGA breast cancer sample set of Caucasian origin [87], n=765 for 
the data normalized per gene, and n=766 for the data normalized per isoform. Genotyping 
platform was Affy6, and gene expression was measured using RNA sequencing. See NB93 for a 
more detailed description. For all sample sets, the genotyping data was processed as follows: 
SNPs with call rates <0.95 or minor allele frequencies < 0.05 were excluded, as were SNPs out of 
Hardy Weinberg equilibrium with P<10
-13
. All samples with a call rate below 80% were 
excluded. Identity by state was computed using the R GenABEL package [90], and closely 
related samples with IBS>0.95 were removed. The SNP and sample filtration criteria were 
applied iteratively until all samples and SNPs met the stated thresholds. 
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Table 1: Associations with breast cancer risk for SNPs showing evidence of differential allelic expression (overall p <0.01) 
a
 Chromosome 
b
 Build 37 position 
c 
Major/minor allele, based on the forward strand and minor allele frequency in Europeans 
d
 Mean minor allele frequency over all European controls in iCOGS 
e
 Per-allele OR for the minor allele relative to the major allele 
f 
One-degree-of-freedom P-value 
 SNPs highlighted in bold are those with associations for overall breast cancer risk reaching p<10
-4
 (significance cut-off after 
Bonferroni correction) 
SNP Chr
a
 Position
b
 Alleles
c
 MAF
d
 OR
e
 _ 
overall risk 
(95%CI) 
P1df
f
_ 
overall 
risk 
OR
e
_ER+ 
(95% CI) 
P1df
f
_ 
ER+ 
OR
e
_ER- 
(95% CI) 
P1df
f
_ 
ER- 
Genes 
rs697004 1 211842808 G/T 0.32 0.96 
(0.94-0.98) 
3.67x10
-04
 0.96 
(0.94-0.99) 
2.84x10
-03
 0.97 
(0.93-1.01) 
1.46x10
-01
 NEK2 
rs13447450 1 91965850 C/T 0.37 0.97 
(0.95-0.99) 
1.16x10
-03
 0.96 
(0.94-0.99) 
1.53x10
-03
 0.96 
(0.92-1.00) 
3.61x10
-02
 CDC7 
rs12125947 1 91990487 T/C 0.49 0.97 
(0.95-0.99) 
1.59x10
-03
 0.97 
(0.95-0.99) 
4.23x10
-03
 0.97 
(0.93-1.01) 
9.47x10
-02
 CDC7 
rs10490250 2 58509628 A/C 0.21 1.03 
(1.01-1.06) 
7.51x10
-03
 1.03 
(1.01-1.06) 
1.85x10
-02 
1.05 
(1.01-1.10) 
4.29x10
-02 
FANCL 
rs13099560 3 48204768 C/T 0.34 0.97 
(0.95-0.99) 
3.99x10
-03
 0.96 
(0.94-0.98) 
8.75x10
-04
 1.00 
(0.96-1.04) 
9.24x10
-01
 CDC25A 
rs11099601 4 
 
84382763 A/G 0.50 1.05 
(1.03-1.07) 
5.62x10
-06
 1.05 
(1.03-1.08) 
5.22x10
-06
 1.07 
(1.03-1.11) 
4.08x10
-04
 HELQ, MRPS18C, 
FAM175A 
rs17355027 4 84388915 C/T 0.08 0.95 
(0.92-0.98) 
4.46x10
-03
 0.95 
(0.91-0.99) 
1.17x10
-02
 0.92 
(0.86-0.98) 
1.55x10
-02
 FAM175A 
rs2362974 5 36156654 C/T 0.12 0.96 
(0.93-0.99) 
5.96x10
-03
 0.97 
(0.93-1.00) 
5.45x10
-02
 0.99 
(0.94-1.06) 
9.56x10
-01
 SKP2 
rs733590 6 36645203 T/C 0.36 1.04 
(1.03-1.06) 
1.77x10
-04
 1.03 
(1.01-1.06) 
7.30x10
-03
 1.05 
(1.01-1.09) 
1.99x10
-02
 CDKN1A 
rs656040 11 65621057 C/T 0.33 1.05 
(1.02-1.07) 
1.52x10
-05
 1.05 
(1.03-1.07) 
5.96x10
-05
 1.03 
(0.99-1.07) 
2.25x10
-01
 SNX32, CFL1, MUS81 
rs570933 15 43824030 T/C 0.29 0.97 
(0.95-0.99) 
7.18x10
-03
 0.97 
(0.95-0.99) 
1.78x10
-02
 0.96 
(0.92-1.00) 
2.89x10
-02
 TP53BP1, MAP1A, 
HISPPD2A 
rs7234479 18 20599564 A/C 0.11 1.05 
(1.02-1.08) 
1.59x10
-03
 1.05 
(1.01-1.09) 
7.57x10
-03
 1.04 
(0.98-1.10) 
1.52x10
-01
 RBBP8 
rs738200 22 28792887 C/T 0.10 1.07 
(1.03-1.10) 
5.32x10
-05
 1.09 
(1.05-1.13) 
7.21x10
-06
 1.03 
(0.97-1.09) 
3.87x10
-01
 TTC28, CHEK2 
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Legends to Tables and Figures 
Table 1. Associations with breast cancer risk for SNPs showing evidence of differential 
allelic expression (overall p <0.01). 
 
Fig. 1. Regional plots of breast cancer risk association at 4q21. Regional plot of association 
result, recombination hotspots and LD for the 4q21: 84,132,874-84,631,193 loci. The index SNP 
rs11099601 is plotted as a blue triangle. Directly genotyped SNPs are represented as triangles 
and imputed SNPs (r
2
>0.3, MAF>0.02) are represented as circles. The LD (r
2
) for the index SNP 
with each SNP was computed based on European ancestry subjects included in the 1000 Genome 
Mar 2012 EUR. Pairwise r
2
 values are plotted using a red scale, where white and red signify r
2
=0 
and 1, respectively. P-values were from the single-marker analysis based on logistic regression 
models after adjusted for age, study sites and the first six principal components plus one 
additional principal component for the LMBC in analyses of data from European descendants. 
SNPs are plotted according to their chromosomal position: physical locations are based on 
GRCh37/hg19. Gene annotation was based on the NCBI RefSeq genes from the UCSC Genome 
Browser. 
Fig. 2. Functional annotation of the 4q21 locus (A) Functional annotations using data from the 
ENCODE and NIH Roadmap Epigenomics projects. From top to bottom, epigenetic signals 
evaluated included DNase clusters in MCF7 and HMEC cells, chromatin state segmentation by 
Hidden Markov Model (ChromHMM) in HMEC, breast myoepithelial cells (BMC) and Variant 
human mammary epithelial cells (vHMEC), where red represents an active promoter region, 
orange a strong enhancer and yellow a poised enhancer respectively (the detailed color scheme of 
chromatin states is described in the UCSC browser), histone modifications in MCF7, HMEC and 
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BMC cell lines ; and overlap between candidate variants and Max binding site in MCF7 cells. All 
tracks were generated by the UCSC genome browser (hg 19). (B) Long-range chromatin 
interactions. From top to bottom, ChIA-Pet interactions for PolII and CTCF in MCF7 cells and 
Hi-C interactions in HMEC cells. The ChIA-PET raw data available on GEO under the following 
accession (GSE63525.K56, GSE33664, GSE39495) were processed with the GenomicRanges 
package. (C) Maps of mammary cell super-enhancer locations as defined in Hnisz et al. are 
shown in HMEC cells. Predicted enhancer-promoter determined interactions in MCF7 and 
HMEC cells, as defined by the integrated method for predicting enhancer targets (IM-PET) are 
shown. (D) RNA-Seq data from MCF7 and HMEC cell lines. The value of the RNA-Seq analysis 
corresponds to the mean RPM value for FAM175A, MRPS18C, HELQ, AGPAT9, HSPE and 
COQ2 from four HMEC and 19 MCF7 datasets, respectively. The annotation was obtained 
through the Bioconductor annotation package TxDb.Hsapiens.UCSC.hg19.knownGene. The 
tracks have been generated using ggplot2 and ggbio library in R. 
Fig. 3. Boxplots representing differential expression of HELQ (A), MRPS18C (B), FAM175A 
(C) and HPSE (D) in breast tissues. Differential expression between normal breast and tumor 
tissue was determined by a Kruskal-Wallis rank sum test using TCGA breast cancer RNAseq 
data from primary tumor, metastasis and adjacent normal. Horizontal bars indicate mean 
expression levels. 
Fig. 4. Boxplots representing expression levels of HELQ (A), MRPS18C (B), FAM175A (C) 
and HPSE (D) in the 5 molecular subtypes (PAM50 classifier) of breast primary tumors. 
Differential expression between normal breast and tumor tissue was determined by a Kruskal-
Wallis rank sum test. Analysis was performed using TCGA breast cancer RNAseq data from five 
molecular subtypes of breast primary tumors : Luminal A (LumA), Luminal B (LumB), Human 
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epidermal growth factor receptor 2-enriched (Her2), Basal-like (Basal) and Normal-like 
(Normal). Horizontal bars indicate mean expression levels. 
Fig. 5. Manhattan plots of association for the eQTL results at the 4q21 locus in normal 
breast and breast cancer tissue. Y-axis shows –log10(P-value) while x-axis shows physical 
position. Circles of various shades of blue represent breast cancer risk associations for all breast 
cancer tumors, ER+ and ER- tumors. Other colored circles represent eQTL results in the 
following datasets: normal breast (NB93, NB116) in various shades of green, breast carcinomas 
in pink (BC241) and red (BC765). Risk association results as well as eQTL results are for both 
imputed and genotyped SNPs for all datasets. 
Fig. 6. Boxplots representing the most significant eQTL results for variant rs11099601 in 
normal breast tissue and breast tumor datasets. Box plots represent the expression levels of 
the indicated transcripts with respect to the rs11099601 genotypes. Expression levels are shown 
for A) HELQ in breast carcinoma BC241 dataset, B) HELQ in breast carcinoma BC765 dataset 
C) HELQ in breast carcinoma BC765 dataset normalized per isoform, D) HELQ in normal breast 
NB93 dataset E) HELQ in normal breast NB93 dataset normalized by gene isoform, F) 
MRPS18C in breast carcinoma BC765 dataset, G) MRPS18C in breast carcinoma BC765 dataset 
normalized per isoform, H) FAM175A in breast carcinoma BC765 dataset and I) HSPE in normal 
breast NB116 dataset. Horizontal bars indicate mean expression level per genotype. r
2
 values 
indicate the percentage of variance in respective gene expression levels explained by rs11099601. 
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Supporting Information Captions 
S1 Fig. Forest plots for the three most significant SNPs (overall P-value <10
-4
). Squares 
indicate the estimated per-allele OR for the minor allele in Europeans. The horizontal lines 
indicate 95% confidence limits. The area of the square is inversely proportional to the variance of 
the estimate. The diamond indicates the estimated per-allele OR from the combined analysis. 
 
S2 Fig. Differential allelic expression mapping of FAM175A and MUS81 loci. (A) (C) The 
most significant cis-regulatory variants mapped by regression analysis in the primary monocyte 
population for FAM175A and MUS81 are rs11099601 (P=5x10
-22
) (A) and rs656040 (P=5.7x10
-
20
) respectively (C). Screenshot of the rs11099601 (B) and rs656040 (D) regions from the UCSC 
genome browser. Tracks display from top to bottom the P-values (-log10) of the allelic 
expression mapping in primary monocytes for each SNP, transcription factor binding (ENCODE 
ChIP-seq data) and average allelic expression across all individuals heterozygous for rs11099601 
(B) and rs656040 (D). 
 
S3 Fig. Distribution of the 5 molecular subtypes (PAM50 classifier) of breast primary 
tumors in the two breast cancer samples sets used for eQTL analysis – BC241 and BC765. 
The distribution of Luminal A, Luminal B, Human epidermal growth factor receptor 2-enriched 
(Her2), Basal-like and Normal-like subtypes is represented as the percentage of the total number 
of samples in each sample set. 
 
S1 Table. List of selected genes and genetic variants associated with differential allelic 
expression. 
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S2 Table. Associations for the 313 genotyped SNPs with overall, ER-positive and ER-
negative breast cancer risk. 
 
S3 Table. Associations for imputed and genotyped SNPs in the 4q21 locus (4q21: 
84,132,874-84,631,193) for overall, ER-positive and ER-negative breast cancer risk. 
 
S4 Table. Regulome DB analysis of SNPs in the 4q21 locus (4q21: 84,132,874-84,631,193) 
with r
2
>0.8 with top associated SNP rs11099601. The scoring scheme refers to the following 
available datatypes: 1a = eQTL + transcription factor (TF) binding + matched TF motif + 
matched DNase Footprint + DNase peak; 1b = eQTL + TF binding + any motif + DNase 
Footprint + DNase peak; 1c = eQTL + TF binding + matched TF motif + DNase peak; 1d = 
eQTL + TF binding + any motif + DNase peak; 1e = eQTL + TF binding + matched TF motif; 1f 
= eQTL + TF binding / DNase peak; 2a = TF binding + matched TF motif + matched DNase 
Footprint + DNase peak; 2b = TF binding + any motif + DNase Footprint + DNase peak; 2c = TF 
binding + matched TF motif + DNase peak; 3a = TF binding + any motif + DNase peak; 3b = TF 
binding + matched TF motif; 4 = TF binding + DNase peak; 5 = TF binding or DNase peak; 6 = 
other. 
 
S5 Table. Description of the BCAC studies with subjects of European origin contributing to 
iCOGs. 
 
S6 Table. Data sources for in silico analyses of the 4q21 breast cancer susceptibility loci 
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Figure 6 
 
 
